Source comparison
TB-500 Cardiac Repair: Protocol Comparison
Dosing Schedule 4mg twice weekly × 4 weeks 2mg twice weekly × 8–12 weeks 2mg once weekly × ongoing Acute protocol suits post-MI intervention; extended protocol targets chronic heart failure remodeling; prophylactic use lacks human evidence Injection Timing Wit
This comparison does not assign a generated winner or score.
- Dosing Schedule
- 4mg twice weekly × 4 weeks
- 2mg twice weekly × 8–12 weeks
- 2mg once weekly × ongoing
- Acute protocol suits post-MI intervention; extended protocol targets chronic heart failure remodeling; prophylactic use lacks human evidence
- Injection Timing
- Within 24–48 hours post-injury
- Begin 2–4 weeks post-injury
- Continuous administration pre-injury
- Early administration (acute protocol) aligns with proliferative phase; delayed start misses angiogenic window
- Typical Research Model
- Rat/mouse MI models, porcine ischemia-reperfusion
- Canine dilated cardiomyopathy, chronic ischemia models
- Athletic conditioning studies (non-cardiac injury)
- Acute MI models produce the strongest evidence base; chronic remodeling data more limited
- Reconstitution Method
- Bacteriostatic water, 2mg/mL
- Bacteriostatic water, 1mg/mL for lower per-injection volume
- Same as acute
- Lower concentration in extended protocols reduces injection site irritation over 8+ weeks
- Expected Outcome Metric
- Infarct size reduction (30–50%), ejection fraction preservation
- Fibrosis attenuation, modest EF improvement (5–10%)
- Theoretical ischemic tolerance. Not clinically validated
- Acute protocols show measurable structural outcomes; prophylactic benefits remain speculative